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Abstract 
Background 
Serum concentration of fetuin A/α2HS-glycoprotein (AHSG) is a good indicator of 
liver cell function and 1-month mortality in patients with alcoholic liver cirrhosis and 
liver cancer. We intended to determine whether decreased serum AHSG levels are 
associated with long-term mortality and whether the follow-up of serum AHSG levels 
can add to the predictive value of the Child-Pugh (CP) and MELD scores. 
Methods 
We determined serum AHSG concentrations in 89 patients by radial 
immunodiffusion. Samples were taken at the time of enrolment and in the 1st, 3rd, 6th, 
and the 12th month thereafter. 
Results 
Forty-one patients died during the 1-year follow-up period, 37 of them had liver 
failure. Data of these patients were analysed further. Deceased patients had lower 
baseline AHSG levels than the 52 patients who survived (293±77 vs. 490±106 µg/ml, 
mean±SD, p<0.001). Of all laboratory parameters serum AHSG level, CP and MELD 
scores showed the greatest difference between deceased and survived patients. The 
cutoff AHSG level 365 µg/ml could differentiate between deceased and survived 
patients (AUC: 0.937±0.025, p<0.001, sensitivity: 0.865, specificity: 0.942) better 
than the MELD score of 20 (AUC: 0.739±0.052, p<0.001, sensitivity: 0.595, 
specificity: 0.729). Initial AHSG concentrations <365 µg/ml were associated with 
high mortality rate (91.4%, relative risk=9.874, 95% C.I.: 4.258-22.898, p<0.001) 
compared to those with ≥365 µg/ml (9.3%). Fourteen out of these 37 fatalities 
occurred during the first month of observation. During months 1-12 low AHSG 
concentration proved to be a strong indicator of mortality (relative risk: 9.257, 95% 
C.I.: 3.945-21.724, p<0.001). Multiple logistic regression analysis indicated that 
decrease of serum AHSG concentration was independent of all variables that differed 
between survived and deceased patients during univariate analysis. Multivariate 
analysis showed that correlation of low serum AHSG levels with mortality was 
stronger than that with CP and MELD scores. Patients with AHSG<365 µg/ml had 
significantly shortened survival both in groups with MELD<20 and MELD≥20 
(p<0.0001 and p=0.0014, respectively). 
Conclusions 
Serum AHSG concentration is a reliable and sensitive indicator of 1-year mortality in 
patients with alcoholic liver cirrhosis that compares well to the predictive value of CP 
score and may further improve that of MELD score. 
Background 
Human fetuin A/α2HS-glycoprotein (AHSG) is a serum glycoprotein with a 
concentration around 450-600 µg/ml in healthy persons. AHSG is a negative acute 
phase reactant [1], accumulates in bone tissue and prevents untoward calcification [2, 
3]. Mice knocked-out for AHS gene exhibit extraosseal calcification [4]. AHSG is a 
natural antagonist of growth factors like insulin [5, 6], transforming growth factor β 
(TGF-β) [7], hepatocyte growth factor/scatter factor (HGF/SF) [8] and inhibits 
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lymphocyte blastic transformation [9]. These findings indicate that AHSG may be 
involved in tissue regeneration [8]. 
 
Since serum AHSG is produced exclusively by hepatocytes in adults [10] and its 
concentration decreases during the acute phase reaction we investigated its changes in 
patients with liver diseases [11, 12]. We found low serum AHSG levels in patients 
with acute alcoholic hepatitis, acute drug-induced hepatitis, chronic autoimmune 
hepatitis, fatty liver, alcoholic and primary biliary cirrhosis, and hepatocellular cancer 
[11, 12, 13]. Alterations were most marked in patients with alcoholic liver cirrhosis 
and hepatocellular cancer [11, 12]. In these patients short-term (i.e. for one month) 
follow-up indicated that serum concentration of AHSG is an excellent indicator of 
liver function and mortality [11]. Serum AHSG levels showed by far the greatest 
difference when we compared laboratory parameters of deceased and survived 
patients with liver cirrhosis and cancer. Decreased levels (≤ 300 µg/ml) were 
associated with high mortality rate (52%, relative risk: 5.497, p < 0.0001). In this 
respect serum AHSG was the best of all laboratory parameters studied. Multiple 
logistic regression analysis indicated that serum AHSG level was independent of all 
parameters that were pathologic in deceased patients [11]. 
 
In this study we tried to determine the usefulness of serum AHSG levels for the long-
term (i.e. up to 1 year) follow-up of patients with alcoholic liver cirrhosis. We 
intended to compare the predictive value of serum AHSG levels to those of the Child-
Pugh (CP) and the Model for End-Stage Liver Disease (MELD) scores. Both score 
has been widely used to estimate the outcome of patients with end-stage liver disease, 
including alcoholic cirrhosis [14-16]. Herein we report that low serum AHSG 
concentration is a reliable and sensitive indicator of 1-year mortality in patients with 
alcoholic liver cirrhosis, comparing to the CP score and may further improve the 
predictive value of the MELD score. 
Methods 
Patients 
Ninety-three patients with alcoholic liver cirrhosis (52 men, 41 women, mean age: 54 
± 13 years, mean ± SD) were tested. They gave written consent approved by the 
Ethical Committee of Semmelweis University. Besides history and appropriate 
clinical symptoms the diagnosis was established by abdominal ultrasonography, and 
liver scan. Exclusion criteria were as follows: cirrhosis of viral origin (HBsAg and 
anti-HCV positivity), or autoimmune aetiology (antinuclear and anti-smooth muscle 
antibodies), liver cancer, and treatment with hepatotoxic drugs. For ethical reasons 
liver biopsy was not performed. Blood samples were taken at the time of enrolment 
and in the 1st, 3rd, 6th and 12th months thereafter. Patients with alcoholic liver cirrhosis 
were only on supportive therapy (diuretics, beta-blockers). 
 
The MELD score was calculated according to the formula of Kamath et al. (3.8 * ln 
serum bilirubine [mg/dl] + 11.2 * ln INR + 9.6 * ln serum creatinine [mg/dl] + 6.4) 
[16]. The CP score of patients was calculated by rating the following parameters 
between 1 and 3: ascites, encephalopathy, prothrombin time (< 15, 15-17, > 17s), 
serum bilirubin (< 2, 2-3, > 3 mg/dl), serum albumin (> 35, 28-35, < 28 g/l) [14, 15]. 
There were 53 patients with grade 1, 20 with grade 2 and 16 with grade 3 
encephalopathy, 27 patients with grade 1, 36 with grade 2, and 26 with grade 3 
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ascites, and 16 patients with CP score 5-6, 46 with 7-9, and 43 with 10 or higher, 
respectively. 
Determination of serum AHSG concentration 
Serum levels of AHSG were determined by radial immunodiffusion (RID) using 
10x10 cm slides as described previously [11]. In brief, 5 µl of patient’s sera diluted to 
1:4 was applied in 11.5 ml of Litex agarose gel (Sigma). Serum samples (1:4 dilution) 
with known concentrations of AHSG served as standards. The incubation was done at 
room temperature for 48 hours. We used anti-AHSG (IgG fraction, Incstar, Cat No. 
81931, 13.7 mg/ml, in a final concentration of 84 µl/11.5 ml gel) as antibody. The 
variation coefficient of the test was 3.6%. 
Other laboratory determinations 
The determination of the erythrocyte sedimentation rate (ESR), hematocrit, 
hemoglobin, white blood cell (WBC), granulocyte and platelet (PLT) count, serum 
bilirubin, serum aspartate aminotransferase (ASAT), alanine aminotransferase 
(ALAT), alkaline phosphatase activities, International Normalisation Rate (INR), total 
serum protein and albumin concentrations was performed using conventional 
standardized methods. Serum levels of α2-macroglobulin, transferrin (TF), 
haptoglobin, and α1-acid glycoprotein/orosomucoid (OROSO) were measured by 
RID. Variation coefficients were 5.0%, and 4.2% for OROSO and TF measurements, 
respectively. C-reactive protein (CRP) concentration was determined by a particle-
enhanced immunoturbidimetric assay (Roche Cobas Integra 4000®). The detection 
limit of the assay was 0.07 mg/l, the coefficient of variation was 3.9% at 108 mg/l 
mean value. 
Statistical analysis 
Paired and unpaired data were analysed by the Wilcoxon and Mann-Whitney U tests, 
respectively. Correlation studies were done by the rank correlation analysis 
(Spearman). Contingency tables were analysed by the Fisher’s exact test. Patients’ 
survival was calculated by the Kaplan-Meyer test and life table analysis. These tests, 
the multiple logistic regression, and the receiver operating characteristic (ROC) curve 
analyses were performed with the SPSS v.11.5 statistical program. The level of p < 
0.01 was considered significant. 
Results 
Relationship between initial serum AHSG concentration and 1-year survival of 
patients with alcoholic liver cirrhosis 
During the one-year follow up 41 out of the 93 patients died. Four patients died of 
intercurrent illnesses unrelated to liver disease (2 of acute left ventricular failure, 1 of 
myocardial infarction, and 1 of pneumonia, respectively). The remaining 37 patients 
died of liver failure, and their data were analysed further. Table 1 Column A shows 
the laboratory data of patients according to the outcome at the end of the one-year 
follow-up period. Compared to survivors we found significantly lower baseline values 
of hematocrit, albumin, TF and AHSG concentrations and significantly higher 
creatinine, bilirubine, INR, CP and MELD score values in deceased patients. Serum 
AHSG level showed one of the greatest differences among all laboratory parameters 
tested. We observed significantly positive correlations of AHSG with hematocrit (r = 
0.406, p= 0.001), albumin (r = 0.366, p = 0.002), TF (r = 0.529, p < 0.001), and 
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negative correlations with serum creatinine (r = -0.312, p = 0.006), INR (r = -0.467, p 
< 0.001), CRP (r = -0.405, p = 0.001), the MELD (r = -0.342, p = 0.001) and CP 
scores (r = -0.522, p < 0.001) whereas no significant correlations were found with the 
other parameters tested. 
Determination of the predictive accuracy of serum AHSG concentration 
We used the ROC curve analysis to determine the optimal cutoff value and test the 
discrimination ability of serum AHSG concentration (Table 2, Column A). Based on 
this curve, the AHSG concentration of 365 µg/ml has been identified as the optimal 
cutoff value for stratification of our patients. At 365 µg/ml the relative risk, sensitivity 
and specificity were higher than those of the cutoff value 300 µg/ml, which was used 
at the short-term study. 
 
Initial AHSG levels below 365 µg/ml were associated a significantly higher risk of 
mortality than those with values above this level (Table 3A). This finding was 
confirmed by the Kaplan-Meyer analysis of patients’ survival (Figure 1). The 
calculated mean survival time of patients with AHSG levels below and above 365 
µg/ml was 3 ± 1 months (mean ± S.E., 95% C.I.: 2 - 4) and 11 ± 1 months (95% C.I.: 
11 - 12, p < 0.0001), respectively (log rank analysis). Life table analysis resulted in a 
median survival of 3.27 months in the former and over 12 months in the latter group, 
respectively (p < 0.0001). The hazard rate of fatal outcome increased with time in 
patients with serum AHSG < 365 µg/ml but not in those with higher AHSG levels 
(Table 4). 
 
There were 6 patients with concomitant alcoholic hepatitis (serum AHSG: 405 ± 85 
µg/ml, mean ± S.D.) whose values did not differ significantly from those without it 
(434 ± µg/ml, n = 83, p = 0.447). In patients with alcoholic hepatitis baseline AHSG 
increased to 454 ± 101 µg/ml (p = 0.500). The statistical comparison (Wilcoxon test), 
however, is not relevant due to small sample size. Seven patients out of the 89 with 
alcoholic cirrhosis continued to drink. Their serum AHSG level (259 ± 97 µg/ml, 
mean ± S.D.) was significantly lower than those who were abstinent (418 ± 129 
µg/ml, n = 82, p = 0.003). Six of them died during the observation period. The only 
one survivor had baseline AHSG concentration above 365 µg/ml. 
 
On enrolment 4 patients had infection: one spontaneous bacterial peritonitis, one 
cholangitis, one erysipelas, and one uroinfection, respectively. Their mean baseline 
serum AHSG level (445 ± 126 µg/ml, mean ± SD) increased to 475 ± 171 µg/ml by 
the time the next sample was taken (Wilcoxon test, p = 0.465). 
 
Serum AHSG levels did not vary considerably throughout the entire observation 
period as it is illustrated in Figure 2. Patients (n = 75) were divided to four quartiles 
according to their baseline AHSG levels. Patients in these four quartiles were 
followed and their final AHSG levels were compared to their baseline quartile values. 
Final AHSG values were within the range of the baseline quartiles (significance of 
difference between baseline and final values in quartiles 1, 2, 3, and 4 were p = 0.022, 
p = 0.248, p = 0.897, and p = 0.126, respectively). Patients with baseline values below 
300 µg/ml almost never reached values above 350 µg/ml, and vice versa. 
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Serum AHSG concentration is an independent predictor of long-term mortality 
Low serum AHSG concentration was associated with high mortality in patients 
studied. Comparison of laboratory data of deceased and survived patients yielded 
significant differences in the MELD score (including creatinine, INR), hematocrit, 
albumin, TF, and AHSG values (Table 1). We used multiple logistic regression 
analysis in order to adjust for the effect of these confounding variables (Table 5A). 
Significant regression coefficient between AHSG levels and 1-year mortality was 
found even after adjustment for the confounding parameters listed above both in the 
model including creatinine and INR and in the one using MELD instead. 
 
Analysis of survival between months 1 and 12 
We have previously demonstrated that low serum AHSG levels are associated high 
mortality during one-month follow-up period [11]. As Figure 2 shows 14 out the 37 
fatalities occurred on the first month. In order to focus on the utility of AHSG levels 
between the 1st and the 12th months we re-run our analyses following exclusion of 
data of patients who died in the first month. 
 
Only creatinine, INR, albumin, TF, AHSG levels, the CP and MELD scores differed 
significantly between deceased and survived patients (Table 1, Column B). In this 
observation period only hematocrit (r = 0.368, p = 0.004), INR (r = -0.404, p < 0.001), 
albumin (r = 0.331, p = 0.007), TF (r = 0.499, p < 0.001), the MELD (r = -0.271, p = 
0.018) and CP (r = -0.431, p < 0.001) scores correlated with AHSG values 
significantly. Low AHSG levels were still associated with an elevated mortality rate 
and a high relative risk to die after the first month of observation (Table 3B). 
 
The Kaplan-Meyer test showed a strong difference between survivals of patients with 
low or high initial AHSG values (Figure 3). The calculated mean survival time with 
AHSG levels below and above 365 µg/ml was 5 ± 1 months (mean ± S.E., 95% C.I.: 
4 - 6) and 11 ± 0 months (95% C.I.: 11 - 12, p < 0.001), respectively (log rank 
analysis). Life table analysis resulted in a median survival of 4.81 months in the 
former and over 12 months in the latter group, respectively (p = 0.001). 
 
The association between low serum AHSG level and 1-12-month mortality was 
further analysed by a multiple logistic regression, in which data were adjusted for the 
confounding variables that significantly differed between deceased and survived 
patients (hematocrit, creatinine, INR, albumin, TF). AHSG levels had significant p 
values in the model using creatinine and INR and in the one using MELD instead. 
When data were adjusted for the confounding variables a significant regression 
coefficient was still found between AHSG levels and 1-12 month mortality both in the 
model with creatinine and INR and in the one with MELD (Table 5 Column B). 
 
Comparison of the predictive accuracies of the CP, MELD scores and serum 
AHSG concentration 
On ROC curve analysis the area under curve (AUC) of serum AHSG exceeded those 
of the CP and MELD scores (Table 2). The sensitivity and specificity of these cutoff 
AHSG values were still above those of CP and MELD. 
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In accordance with most observations we stratified our patients at the CP score of 10 
[14-15]. The MELD score value ≥ 20 is generally accepted as an indication for liver 
transplantation [16]. Therefore we stratified MELD at 20. Patients with MELD ≥ 20 
had higher relative risk to die within a year than those with smaller values but this risk 
was below what we found for AHSG < 365 µg/ml (Table 2). The risk of lethal 
outcome in patients with CP < 10 was comparable with those of low baseline AHSG 
values. 
 
Figure 4 illustrates the significant difference between survival of patients with MELD 
< 20 or ≥ 20 and serum AHSG > or ≥ 365 µg/ml. In order to analyse the joint-effect 
of MELD and serum AHSG on survival o patients with liver cirrhosis patients were 
divided to four groups according to these critical values. Compared to group 1 
(MELD < 20 and serum AHSG ≥ 365 µg/ml) group 2 (MELD < 20 and serum AHSG 
< 365 µg/ml) had a marginally significantly shortened survival: 5 ± 1 months, 95% 
C.I.: 3-6 months vs. 12 months, 95% C.I. 11 - 12 months (log rank analysis: p < 
0.001). The survival of patients in group 3 (MELD ≥ 20 and serum AHSG ≥ 365 
µg/ml) was also reduced (mean survival time: 8 ± 2 months, 95% C.I.: 5 - 11 months, 
log rank analysis: p = 0.008. Group 4 (MELD ≥ 20 and serum AHSG < 365 µg/ml) 
had the worst prognosis: mean survival time: 2 ± 1 months (95% C.I.: 1 - 3 months, 
log rank analysis: p = 0.00001. Survival between groups 3 and 4 also differed 
significantly (p = 0.001). 
 
Finally we set up a multiple logistic regression model to compare the predictive 
values of serum AHSG concentration to those of the CTP and MELD scores (Table 
6). Serum AHSG values had the strongest association with mortality. 
 
Discussion 
Previously we found serum AHSG to be an outstanding laboratory parameter of liver 
function an independent predictor of short-term mortality during the 1-month follow-
up period [11]. Data gained during the first month of the present study supported our 
previous observations on short-term survival. Our present data suggest that the 
initially low serum AHSG concentration has an impact on long-term mortality as 
well. Excluding fatal outcomes that occurred during the first month survival analysis 
showed that low serum AHSG levels were still markedly associated with mortality. 
The marked difference of mean survival time between patients with low and normal 
AHSG levels indicated by the Kaplan-Meyer and life table analysis were in complete 
accordance with these observations. 
 
The proinflammatory cytokines interleukin (IL)-1, IL-6, and tumour necrosis factor-α 
(TNFα) are known to enhance the synthesis of the positive (CRP, OROSO) and 
down-regulate that of the negative acute phase reactants in rat liver and human 
HepG2 cells [17, 18]. Our short-term follow-up results suggested that the decreased 
serum AHSG concentration was associated rather with hepatocyte dysfunction than 
with the acute phase reaction [11]. During the 1-year follow up, a strong positive 
correlation with the negative acute phase protein TF and a negative correlation with 
the positive acute phase protein CRP have been observed. This latter correlation, 
however, was not significant between months 1-12. We found no significant 
correlation with the positive acute phase reactant OROSO. This suggests that the 
acute phase reaction is neither a determinant of the concentration of these proteins nor 
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affects the long-term outcome in patients with liver cirrhosis. Thus in accordance with 
our earlier findings low serum AHSG concentration reflects rather hepatocyte 
dysfunction than the acute phase reaction [11]. 
 
It has to be mentioned, however, that serum AHSG concentration is not decreased in 
every liver disease. There is no change in acute A, B, or Epstein-Barr virus hepatitis, 
and, moreover, there is a paradoxic elevation of AHSG levels in sera of patients with 
chronic C virus hepatitis [11, 12, 19]. Therefore serum AHSG concentration has 
probably no prognostic significance in these diseases. 
 
Since its introduction in 2001 the MELD score has been used widely to predict the 
outcome of patients with end-stage liver disease [16]. The advantages and 
disadvantages of MELD and its comparison to the classical CP score have been 
reviewed extensively [14-15]. Though the clinical usefulness of MELD is established 
well modifications have been still recommended [20]. We have also found that CP 
performs slightly better than MELD. Logistic regression studies indicate that the CP, 
MELD and serum AHSG levels predict mortality somewhat independently from each 
other. 
 
Conclusions 
The sensitivity, specificity and predictive values of serum AHSG concentration 
exceed those of the CP and the MELD scores. Although not in wide use the 
measurement serum AHSG concentration is simple. Serum AHSG levels may add to 
the power of MELD. A study performed on a large series of patients is needed to 
decide whether the combination of these parameters will result in an improved 
predictive value, and if so, how serum AHSG levels could be formulated. 
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Figures 
 
 
 
Figure 1 Patients with serum AHSG concentration < 365 µg/ml have lower 
survival rate than those with ≥ 365 µg/ml throughout the 1-year observation 
period. 
Serum AHSG concentration < 365 µg/ml (green line, n = 35), serum AHSG 
concentration ≥ 365 µg/ml (magenta line, n = 54), log rank test, p < 0.001 
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Figure 2 Serum AHSG concentration did not change considerably during the 1-
year observation period. 
Values represent mean ± SEM. Comparison was performed by the Wilcoxon test. 
Baseline values of patients who died during the first month of observation (n = 14) 
were omitted from the analysis. 
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Figure 3 Patients with serum AHSG concentration < 365 µg/ml have lower 
survival rate than those with ≥ 365 µg/ml between months 1-12. 
Serum AHSG concentration < 365 µg/ml (green line, n = 21), serum AHSG 
concentration ≥ 365 µg/ml (magenta line, n = 54), log rank test p < 0.001 
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Figure 4 The joint effect of serum AHSG concentration and the MELD score on 
the survival of patients with alcoholic liver cirrhosis. 
Group 1 (green line): MELD < 20, serum AHSG ≥365 µg/ml (n = 46), group 2 
(magenta line): MELD < 20, serum AHSG < 365 µg/ml (n = 16), group 3 (yellow 
line): MELD ≥ 20, serum AHSG ≥ 365 µg/ml (n = 7), and group 4 (grey line): MELD 
≥ 20, serum AHSG < 365 µg/ml (n = 20), respectively. Compared to group 1, the 
survival is significantly shortened in groups 2, 3, and 4. Compared to group 1 the 
Odds Ratios for lethal outcome in groups 2, 3, and 4 are: 157.5 (95% C.I.: 20.28 - 
1223, p < 0.001), 16.875 (95% C.I.: 2.149 - 132.5, p = 0.012), and 405.0, 95% C.I.: 
34.53 - 4749 p < 0.0001), respectively. 
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Table 1 Comparison of laboratory parameters of deceased and survived patients 
with alcoholic liver cirrhosis during the one-year follow-up period (Column A) 
and between months 1 and 12 (Column B) 
 (A) 
1-year follow-up period 
(B) 
Follow-up between months 1-12  
Parameter Deceased 
patients 
mean ± SD 
n = 37 
Survived 
patients 
mean ± 
SD 
n = 52 
p Deceased 
patients 
mean ± SD 
n = 23 
Survived 
patients 
mean ± SD 
n = 52 
p 
Age, years 57 ± 14 52 ± 12 0.056 58 ± 15 52 ± 12 0.056 
Erythrocyte 
sedimentation 
rate, mm/h 
57 ± 32 40 ± 30 0.019 59 ± 34 40 ± 30 0.030 
Hematocrit, l/l 0.32 ± 0.1 0.37 ± 0.1 0.004 0.33 ± 0.1 0.36 ± 0.1 0.029 
Hemoglobin, g/l 112 ± 18 121 ± 24 0.053 113 ± 18 121 ± 24 0.137 
White blood cell 
count, µl-1 
9582 ± 
5076 
7706 ± 
4640 
0.016 8960 ± 
5102 
7706 ± 
4639 
0.082 
Granulocyte 
count, µl-1 
6308 ± 
4080 
4788 ± 
3241 
0.080 5409 ± 
3253 
4787 ± 
3240 
0.311 
Platelet count, µl-
1 
16061 ± 
117289 
177370 ± 
91742 
0.228 153480 ± 
114813 
177370 ± 
91742 
0.185 
Serum creatinine, 
mg/dl 
1.31 ± 0.65 0.96 ± 0.29 0.002 1.32 ± 0.62 0.97 ± 0.28 0.001 
Serum bilirubin, 
mg/dl 
10.7 ± 1.0 6.90 ± 10.1 0.008 7.8 ±1.3 7.13 ± 171 0.041 
Serum aspartate 
aminotransferase, 
U/l 
113 ± 80 122± 171 0.201 107 ± 81 122 ± 10 0.485 
Serum alanine 
aminotransferase, 
U/l 
79 ± 137 143 ± 351 0.852 97 ± 173 142 ± 350 0.763 
Alkaline 
phosphatase, U/l 
425 ± 422 371 ± 284 0.987 404 ± 479 371 ± 283 0.571 
INR 1.73 ± 0.7 1.25 ± 0.4 < 
0.001 
1.64 ± 0.7 1.26 ± 0.4 < 
0.001 
Total protein, g/l 63 ± 7 68 ± 10 0.453 68 ± 7 68 ± 9 0.815 
Albumin, g/l 31 ± 7 37 ± 6 0.001 31 ± 7 36 ± 7 0.008 
CRP, mg/l 62 ± 78 42 ± 78 0.061 65 ± 103 43 ± 79 0.505 
α2-
macroglobulin, 
mg/dl 
315 ± 87 339 ± 123 0.588 335 ± 97 340 ± 123 0.851 
Haptoglobin, 
mg/dl 
186 ± 260 201 ± 150 0.035 203 ± 280 200 ± 151 0.108 
Transferrin, 
mg/dl 
148 ± 52 216 ± 86 < 
0.001 
148 ± 60 217 ± 87 0.003 
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α1-acid 
glycoprotein, 
mg/dl 
94 ± 51 112 ± 53 0.049 93 ± 54 112 ± 54 0.076 
CP score 11 ± 2 7 ± 2 < 
0.001 
11 ± 2 8 ± 2 < 
0.001 
MELD score 20 ± 9 13 ± 5 < 
0.001 
20 ± 8 13 ± 6 < 
0.001 
AHSG, µg/ml 293± 77 490 ± 106 < 
0.001 
303 ± 91 490 ± 91 < 
0.001 
p: significance calculated by the Mann-Whitney test 
 
Table 2 Comparison of the sensitivity, specificity and predictive values of CP, 
MELD scores and serum AHSG in patients with alcoholic liver cirrhosis 
 (A) 
1-year follow-up period 
(B) 
Follow-up between 
months 1-12 
CP score 
AUC ± SD 
p 
95% C.I. 
 
0.865 ± 0.040 
< 0.001 
0.787 - 0.943 
 
0.855 ± 0.050 
< 0.001 
0.757 - 0.953 
MELD score 
AUC ± SD 
p 
95% C.I. 
 
0.739 ± 0.052 
< 0.001 
0.637 - 0.871 
 
0.740 ± 0.058 
0,001 
0.626 - 0.854 
Serum AHSG 
AUC ± SD 
p 
95% C.I. 
 
0.937 ± 0.025 
< 0.001 
0.889 - 0.986 
 
0.908 ± 0.035 
0.001 
0.839 - 0.978 
CP score < 10, ≥ 10 
Relative Risk 
p 
95% C.I. 
Sensitivity at this cutoff value 
Specificity at this cutoff value 
 
3.878 
< 0.001 
1.998 - 7.527 
0.753 
0.827 
 
4.838 
< 0.001 
2.009 - 11.649 
0.675 
0.755 
MELD score < 20, ≥ 20 
Relative Risk 
p 
95% C.I. 
Sensitivity at this cutoff value 
Specificity at this cutoff value 
 
2.205 
0.002 
1.318 - 3.689 
0.595 
0.729 
 
2.4167 
0.011 
1.229 - 4.952 
0.587 
0.720 
AHSG < 365 µg/ml, ≥ 365 µg/ml 
Relative Risk 
p 
95% C.I. 
Sensitivity at this cutoff value 
Specificity at this cutoff value 
 
9.874 
< 0.001 
4.258 - 22.898 
0.865 
0.942 
 
9.257 
< 0.001 
3.945 - 21.724 
0.783 
0.936 
AHSG < 300 µg/ml, ≥ 300 µg/ml 
Relative Risk 
 
4.209 
 
4.813 
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p 
95% C.I. 
Sensitivity at this cutoff value 
Specificity at this cutoff value 
< 0.001 
2.675 - 6.622 
0.594 
0.981 
< 0.001 
2.813 - 8.233 
0.478 
0.972 
 
Table 3 Effect of initial serum AHSG level on the survival of patients with 
alcoholic liver cirrhosis throughout the 1-year observation period (A) and 
between months 1-12 (B) 
A 
 Deceased Survived Total Mortality rate % 
Serum AHSG < 365 µg/ml 32 3 35 94.1 
Serum AHSG ≥ 365 µg/ml 5 49 54 9.3 
Total 37 52 89  
p < 0.001, Relative Risk: 9.874 (95% C.I.: 4.258 - 22.898) 
B 
 Deceased Survived Total Mortality rate % 
Serum AHSG < 365 µg/ml 18 3 21 85.7 
Serum AHSG ≥ 365 µg/ml 5 49 54 9.3 
Total 23 52 75  
p < 0.001, Relative Risk: 9.257 (95% C.I.: 3.945 - 21.724) 
 
Table 4 Fatality risk over the one-year observation period in patients with serum 
AHSG levels above and below 365 µg/ml 
Hazard rate at AHSG < 365 µg/ml AHSG ≥ 365 µg/ml 
1 month 0.500 ± 0.129 0.000 ± 0.000 
3 months 0.897 ± 0.222 0.077 ± 0.384 
6 months 0.909 ± 0.362 0.020 ± 0.000 
12 months and after* 0.943 ± 0.420 0.000 ± 0.000 
* Since the observation period was limited to 12 months hazard rate at this time 
interval should be considered as an interpolation. Hazard rate: mean ± SE 
 
Table 5 Association of low fetuin A/2HS-glycoprotein levels with 1-year 
mortality of patients with alcoholic liver cirrhosis calculated by adjusted 
multiple logistic regression* 
 (A) 
1-year follow-up period 
(B) 
Follow-up between months 1-12
Variable P* P* P* P* 
Hematocrit 0.482 0.597 0.463 0.453 
Serum albumin 0.271 0.832 0.249 0.994 
Transferrin 0.706 0.838 0.608 0.843 
Serum creatinine - 0.633 - 0.806 
INR - 0.290 - 0.262 
MELD< 20, ≥ 20 0.172 - 0.165 - 
AHSG < 365 µg/ml, 
≥ 365 µg/ml 
0.004 0.010 0.021 0.012 
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Odds Ratio of 
AHSG < 365 µg/ml, 
≥ 365 µg/ml 
58.82 
95% C.I.: 
3.703 - 
950.8 
49.35 
95% C.I.: 
2.497 - 
975.6 
28.91 
95% C.I: 
1.661 - 503.4 
32.59 
95% C.I.: 1.502 
- 707.0 
Model fit p = 0.015 p = 0.068 p = 0.002 p = 0.012 
* P value of regression coefficient, adjusted for variables significantly associated with 
mortality at univariate analysis (Table 1). 
 
Table 6 Association serum AHSG concentration, the CTP and MELD scores 
with mortality of patients with alcoholic liver cirrhosis calculated by adjusted 
multiple logistic regression 
 1-year follow-up Months 1-12 
Variable p* OR 
95% C.I. 
p* OR 
95% C.I. 
CTP score < 10, ≥ 10 0.004 17.54 
2.556 - 119.9 
0.005 15.58 
2.333 - 104.1 
MELD score < 20, ≥ 20 0.110 - 0.120 - 
AHSG < 365 µg/ml, ≥ 365 
µg/ml 
< 0.001 170.6 
22.73 - 1280 
< 0.001 89.43 
11.89 - 672.6 
Model fit p = 0.114 p = 0.001 
*: p value of regression coefficient 
 
